Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality.
Methods: PubMed, Embase, Web of science, Cochrane Library and the Epistemonikos COVID-19 Living Overview of Evidence database (L.OVE) were searched to aggregate currently published studies. Cochrane risk of bias tool and ROBINS-I tool were used to assess the risk of bias of randomized controlled study and cohort study respectively. Odds radios (ORs) with 95% confidence interval (CIs) were combined for dichotomous variables. Publication bias was assessed by Egger's test and funnel plots.
Results: A total of 184 articles were retrieved from the included databases and 17 studies were included into the final analysis. Pooled analysis showed that azvudine significantly reduced mortality risk in COVID-19 patients compared with controls (OR: 0.41, 95%CI 0.31-0.54, p < 0.001). Besides, either mild to moderate or severe COVID-19 patients could benefit from azvudine administration. There was no significant difference in the incidence of ICU admission (OR: 0.90, 95%CI 0.47-1.72, p = 0.74) and invasive ventilation (OR: 0.94, 95%CI 0.54-1.62, p = 0.82) between azvudine and control group. The incidence of adverse events was similar between azvudine and control (OR: 1.26, 95%CI 0.59-2.70, p = 0.56).
Conclusions: This meta-analysis suggests that azvudine could reduce the mortality risk of COVID-19 patients, and the safety of administration is acceptable.
Trial Registration: PROSPERO; No.: CRD42023462988; URL: https://www.crd.york.ac.uk/prospero/ .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893615 | PMC |
| http://dx.doi.org/10.1186/s12985-024-02316-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantifying Barriers to Diabetic Eye Screening: A Two-Center Study at the University of California.
Diabetes Care
September 2025
Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA.
Objective: This study aimed to evaluate the diabetic eye disease screening continuum at two academic centers and identify its barriers.
Research Design And Methods: We analyzed health records from the University of California, San Francisco and University of California, Irvine to identify primary care patients needing diabetic eye screening. We tracked referrals, screenings, diagnoses, and treatments to evaluate predictors and the impact of an automated referral system.
Predictors of health care utilization in patients with post-acute sequelae of COVID-19 (PASC).
PLoS One
September 2025
The Permanente Medical Group, Pleasanton, California, United States of America.
Background: Research on Post-acute sequelae of COVID (PASC) has focused on the prevalence of symptoms, leaving gaps in our understanding of predictors of health care seeking.
Objective: To identify clinical and sociodemographic characteristics associated with PASC care seeking.
Methods: Retrospective cohort study of adult patients with COVID-19 diagnosis between January 1, 2021 and June 30, 2022 in a community-based comprehensive health care delivery system at 21 hospitals and medical clinics in Northern California.
Measuring High-sensitive Cardiac Troponin Concentrations Predicted Hospital Deaths in Children With Severe Coronavirus Disease 2019.
Pediatr Infect Dis J
September 2025
From the Department of Pediatric Intensive Care Unit, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Background: Antiviral drugs and coronavirus disease 2019 (COVID-19) vaccines have significantly reduced COVID-19-related hospitalizations and deaths in infected children. However, COVID-19 continues to pose a major mortality risk in young children. High-sensitive cardiac troponin (Hs-cTn) is a specific marker of myocardial cell damage.
View Article and Find Full Text PDFA multi-omics recovery factor predicts long COVID in the IMPACC study.
J Clin Invest
September 2025
The University of Texas at Austin, Austin, United States of America.
Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.
Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.
Caregiver Burden and 30-Day Emergency Department Revisits.
JAMA Netw Open
September 2025
Centre de recherche intégrée pour un système apprenant en santé et services sociaux, Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Lévis, Québec, Canada.
Importance: Caregivers of community-dwelling older adults play a protective role in emergency department (ED) care transitions. When the demands of caregiving result in caregiver burden, ED returns can ensue.
Objective: To develop models describing whether caregiver burden is associated with ED revisits and hospital admissions up to 30 days after discharge from an initial ED visit.